Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX(R) AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castration-Resistant Prostate Cancer

Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized

SAN DIEGO and REDWOOD CITY, Calif., March 30, 2018 -- (Healthcare Sales & Marketing Ne... Diagnostics, Oncology, Reimbursement Epic Sciences, Genomic Health, Oncotype DX AR-V7, Nucleus Detect, mCRPC

Source: HSMN NewsFeed - March 30, 2018 Category: Pharmaceuticals Source Type: news